Recently we have seen evidence of improved cancer control in high-risk patients treated with external beam radiotherapy with a brachytherapy boost to the prostate. This has been demonstrated with both HDR brachytherapy boost and with LDR brachytherapy boost.
Can the same cancer control be obtained with intensity-modulated radiation therapy (IMRT) and a boost to the prostate delivered with stereotactic body radiation therapy (SBRT)?
Anwar et al. reported the outcomes of 48 intermediate and high-risk patients treated with SBRT boost therapy between 2006 and 2012 at the University of California San Francisco. Of these 48 patients, 34 (71 percent) were high risk, and 14 (29 percent) were intermediate risk.
The treatment consisted of:
- IMRT: 45 to 50 Gy in 25 fractions to the entire pelvis if the risk of lymph node involvement was > 15 percent, otherwise with a 1 cm margin.
- SBRT boost: 9.5 or 10.5 Gy in 2 fractions to the prostate, seminal vesicles + a 2 mm margin, 0 mm on the rectal side.
- Heterogeneous planning was used to mimic HDR brachytherapy dosimetry.
- Gold fiducials were used for daily (IMRT) and intra-fractional (SBRT) image tracking.
- Intermediate-risk patients had 4 to 6 months of adjuvant hormone therapy.
- High-risk patients had up to 2 years of adjuvant hormone therapy.
After a median of follow-up of 42.7 months, they reported the following results:
- 5-year biochemical no evidence of disease: 90 percent
- PSA nadir (median): 0.05 ng/ml
- 2 patients had a PSA bounce over 2 ng/ml, which declined with longer follow-up
- 4 patients had a clinical recurrence outside of the radiation field
- Local control (within the radiation field) was 100 percent.
- Acute toxicity:
- Urinary, grade 2: 17 percent
- Rectal, grade 2: 10 percent
- Late toxicity:
- Urinary, grade 2: 25 percent; grade 3: 1 patient
- Rectal, grade 2 or higher: none
Clearly, these are excellent results for cancer control. The table below shows outcomes in similar trials of SBRT boost treatments and of SBRT monotherapy:
Compared to these other small trials, Anwar et al. used significantly higher effective doses of radiation and got perhaps better control (remembering that almost a third were intermediate risk), but late-term urinary toxicity was high. Lin et al. used lower doses, had similar control in their all high-risk group trial at 3 years, and none suffered from late-term urinary toxicity. Katz and Kang treated consecutive high-risk patients with SBRT boost and with monotherapy, respectively, but had the same cancer control in both groups, and the late-term urinary toxicity was not significantly different. Katz and Kang concluded that the SBRT boost accomplished nothing compared to the monotherapy, and also found that ADT use did not contribute to cancer control in his patients. He treated all subsequent high-risk patients with SBRT monotherapy only and without ADT.
We can also look at the Anwar outcomes next to those of a recent LDR brachytherapy boost therapy trial (ASCENDE-RT) and an HDR monotherapy trial (Hoskin et al.) in the table below:
SBRT boost therapy seems to provide similar rates of cancer control, but with less late-term urinary toxicity compared to brachy boost therapy or HDR-BT monotherapy.
In an interesting twist, Memorial Sloan-Kettering Cancer Center is running a clinical trial of SBRT supplemented with an LDR-BT boost to the prostate in intermediate-risk men (NCT02280356). I would guess that this would have considerable toxicity, but the clinical trial will prove or disprove that hypothesis.
So far, trials of SBRT boost therapy are too small to draw anything but provisional conclusions. There is a larger trial nearing completion at Georgetown University Hospital next month. Based on these pilot studies, SBRT boost therapy seems to be capable of providing good cancer control in high-risk patients and may be able to accomplish that with less toxicity than brachytherapy-based treatments. As we’ve seen, SBRT monotherapy and HDR brachy monotherapy are emerging therapies for high-risk patients as well. It would certainly be a lot more convenient to accomplish the same cancer control, at lower cost, and with perhaps less toxicity using just 5 SBRT monotherapy treatments instead of 27 treatments with SBRT boost. Only a prospective, randomized, comparative clinical trial can tell us whether one therapy is better than another. The most appropriate radiation dose level, dose constraints, the size of margins, lymph node treatment, and whether adjuvant ADT provides any benefit are variables yet to be determined.
This is an area of active investigation. If readers are interested in participating in a clinical trial of SBRT boost therapy, below is a list of open trials and their locations:
Fountain Valley, CA (NCT02016248)
Sacramento, CA (NCT02064036)
San Francisco, CA (NCT02546427)
Miami, FL (NCT02307058)
Park Ridge, IL (NCT01985828)
Boston, MA (NCT01508390)
Madison, WI (NCT02470897)
Scottsdale, AZ (NCT02339948)
Ft. Myers, FL (NCT02339948)
Plantation, FL (NCT02339948)
Farmington Hills, MI (NCT02339948)
Myrtle Beach, SC (NCT02339948)
Sydney, Australia (NCT02004223)
Gliwice, Poland (NCT01839994)
Poznan, Poland (NCT02300389)
Link to original content located: here.